Immunovant Widens Net Loss in Fiscal Q3
7:18AM ET 2/04/2022 MT NewswiresImmunovant (IMVT) reported a fiscal Q3 net loss Friday of $0.36 per diluted share, widening from a per-share loss of $0.32 a year earlier. Analysts polled...
Immunovant (IMVT) reported a fiscal Q3 net loss Friday of $0.36 per diluted share, widening from a per-share loss of $0.32 a year earlier. Analysts polled...
Eva Renee Barnett, Chief Financial Officer, on January 07, 2022, sold 29,959 shares in Immunovant (IMVT) for $217,203. Following the Form 4 filing with the...
Julia G. Butchko, Chief Development and Technology Officer, on January 07, 2022, sold 55,318 shares in Immunovant (IMVT) for $401,056. Following the Form 4...
Number of Employees | N/A |
Recent SEC Filing | 04/29/2022![]() |
Price Open | $4.09 |
Previous Close | $4.04 |
52 Week Range | $3.71 - 16.05 |
Market Capitalization | $470.2 M |
Shares Outstanding | 116.4 M |
Sector | Health Technology |
Industry | Biotechnology | Next Earnings Announcement | 06/07/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | N/A |
Earnings per Share | -$1.30 |
Beta vs. S&P 500 | N/A |
Revenue | N/A |
Net Profit Margin | N/A |
Return on Equity | -30.63% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |